Center InformationBrittany Depp, MA, CCRP
Clinical Research Specialist
Washington University in St. Louis
Center for Clinical Studies
660 S. Euclid, Campus Box 8009
St. Louis, MO 63110
Currently Enrolling Trials
The Center for Clinical Studies (CCS) supports the effective, efficient and safe conduct of clinical trials at Washington University School of Medicine, one of the nation’s leading academic medical research institutions. The CCS helps to recruit patients into appropriate clinical trials and provides sponsoring institutions with the full spectrum of clinical trial support services.
The CCS offers study volunteers the opportunity to advance medical science by participating in clinical trials. Volunteers may visit the Research Participant Registry at vfh.wustl.edu to learn about the participation experience.
The CCS is a one-stop, full-service resource for companies committed to the highest-quality clinical studies. The CCS provides sponsors with access to nationally renowned investigators and top-quality study coordinators and clinical trial participants, as well as a full spectrum of support services. Services include:
- Study placement
- Regulatory and budget services
- Targeted patient recruitment
- Expert study coordination
- Ancillary Services
Please visit ccs.wustl.edu for more information.
Washington University School of Medicine is among the world's largest academic biomedical research centers. From its central location in St. Louis, Mo., the school's world-renowned clinical investigators, nationally ranked hospital partners, cutting-edge research facilities and large, diverse patient population form the ideal environment for sponsoring clinical research.
World-Renowned Clinical Investigators
- 1,727 faculty - more than 200 in clinical research
- 100 faculty named in America's Top Doctors, 2008
- Nation's third-largest academic clinical practice – more than 1,000 physicians in more than 50 specialties
Ideal Enrollment Environment
- 753,363 on-campus patient visits, FY 2008
- Patients drawn from 13 area hospitals
- Catchment area of nine midwestern states and beyond
- High patient compliance and retention rates
- Comprehensive services for industry partners including study placement, strategic recruitment and IRB submission through the University's Center for Clinical Studies
Where Bench and Bedside Meet
- Top five nationally in National Institutes of Health funding ($346 million in FY 2008)
- 1,500 ongoing clinical trials
- Affiliated with Barnes-Jewish Hospital and St. Louis Children's Hospital, both ranked among the nation's 10 best, with 1,478 beds combined, and the Alvin J. Siteman Cancer Center, a National Cancer Institute Comprehensive Cancer Center
Exceptional Data Integrity
As one of the world's leading academic research institutions, Washington University School of Medicine upholds an uncompromising commitment to quality in all of its efforts, including research.
- Expediting study placement
- Identifying outstanding clinical investigators and researchers with unique skills, training or equipment
Regulatory and Budget Services
- Facilitating all IRB and regulatory services
- Comprehensive study budget preparation and negotiation
- Consultation as needed between the PI and clinical study sponsor
Targeted Patient Recruitment
- Subject recruitment, prescreening and enrollment support
- Access to a centralized database of potential patient volunteers to facilitate rapid accrual of and access to study participants
- Assistance with creating a comprehensive approach to maximizing recruitment efforts
- Advertising development and placement
Expert Study Coordination
- Providing the full range of study coordinator services from site qualification visits to study close-out
The Center for Clinical Studies (CCS) supports the effective, efficient and reliable evaluation of new pharmaceuticals and medical devices in collaboration with sponsoring organizations. The CCS is a one-stop, full-service resource providing a full spectrum of support services in collaboration with the School of Medicine’s Inpatient and Outpatient Research Units and the Core Laboratory for Clinical Studies
Outpatient Clinical Trials Unit (CTU)
- 7,000 square feet of dedicated outpatient research space
- Six fully equipped exam rooms and two long-term areas for extended study visits
- Phlebotomy and lab processing
- Space for monitoring visits
- Fully stocked crash cart
Clinical Research Unit
The Washington University Clinical Research Unit (CRU) is an on-campus comprehensive support center for observational/extended stay and outpatient adult research. The CRU provides observational and extended stay research space, research nursing, and core laboratory services.
Since its inception in 1891, Washington University School of Medicine has been a pioneer and leader in biomedical research, contributing countless major advances in nearly every area of medical inquiry. The school’s faculty is internationally recognized for their leadership in landmark national and international clinical studies. Today, more than 1,500 clinical trials, conducted in strict compliance with FDA regulations, are in progress.
The Washington University School of Medicine faculty is comprised of world leaders in research in the following areas:
- Bone and mineral diseases
- Cardiovascular disease
- Child health
- Gastrointestinal diseases
- Genome sequencing
- Infectious diseases
- Molecular design
- Pulmonary disease
- Renal disease
Study patients are drawn largely from the clinical activities of Washington University Medical Center. Washington University operates the nation's third largest academic clinical practice group, Washington University Physicians. The group is made up of 976 physicians in more than 50 specialties and subspecialties. Washington University physicians provide comprehensive care at more than 35 clinical office sites throughout the St. Louis area.
Washington University Physicians Clinical Activities, FY 2008:
- Physician Outpatient Visits: 753,363
- Hospital Admissions: 68,681 (BJH, SLCH)
- Outpatient Procedures: 560,412
Through its affiliations with Barnes-Jewish Hospital and St. Louis Children's Hospital, Washington University also has access to the patient pool of BJC HealthCare. BJC is a consortium of 13 area hospitals, including Barnes-Jewish and St. Louis Children's hospitals, and is one of the nation's largest nonprofit healthcare providers. In total, BJC experiences roughly 727,000 patient contacts annually (combined hospital admissions, home health visits and emergency department visits).
Washington University’s patient pool covers urban, suburban and rural areas and represents a full range of ages and ethnic and socioeconomic parameters. Within the city of St. Louis, 52 percent of the population is African-American; in the region as a whole, 24 percent of the population is considered diverse. St. Louis gains diversity as a major national center for refugee placement. With nearly 85,000 refugees, St. Louis city is second in the nation for the density of new arrivals to native born. To serve patients and their families, Barnes-Jewish Hospital’s Refugee Health and Interpreter Services offers a team of nearly 30 interpreters who provide services through at least 32,000 encounters each year in more than 60 languages.
Hospitals and Affiliates
Washington University School of Medicine is affiliated with several elite patient-care institutions: Barnes-Jewish Hospital, St. Louis Children's Hospital and the Alvin J. Siteman Cancer Center. Together with the Central Institute for the Deaf, these institutions make up Washington University Medical Center.
Barnes-Jewish Hospital, a 1,228-bed facility, is the largest hospital in Missouri. The hospital is ranked by U.S. News & World Report as ninth nationally among an elite group of the nation's best academic hospitals. Barnes-Jewish ranks in the top 10 in the areas of ear/nose/throat (5), endocrinology (7), heart and heart surgery (10), kidney disease (8), neurology and neurosurgery (7), ophthalmology (10) and respiratory disorders (6). It ranks among the top 20 in the areas of cancer (19), digestive disorders (18), geriatrics (14), orthopedics (14), psychiatry (15), rheumatology (17) and urology (12). The medical staff is composed exclusively of Washington University School of Medicine faculty physicians.
Please visit barnesjewish.org for more information.
St. Louis Children's Hospital
St. Louis Children's Hospital, staffed exclusively by Washington University School of Medicine faculty physicians, is ranked among the best children's hospitals in the country. The hospital provides a full range of pediatric specialty and subspecialty services to a primary service region covering six states. The hospital has 250 licensed beds, including a 26-bed pediatric intensive care unit, a 75-bed Level III newborn intensive care unit and a five-bed pediatric bone marrow transplant unit. Child magazine ranks St. Louis Children's Hospital seventh in the country and second in pulmonary medicine, sixth in neonatology and eighth in orthopedic care. U.S. News & World Report ranks Children's Hospital 14th nationally.
Please visit stlouischildrens.org for more information.
Barnes-Jewish Hospital and St. Louis Children's Hospital are members of BJC HealthCare, one of the largest nonprofit healthcare organizations in the United States. BJC is a regional, nonprofit healthcare organization that provides community-based and academic healthcare services through 13 hospitals and more than 100 inpatient and ambulatory care sites in Missouri and southern Illinois. BJC provides a full continuum of services, including wellness and health promotion; primary, acute and ambulatory care; skilled nursing; long-term care; home healthcare; and hospice care.
Please visit bjc.org for more information.
The Alvin J. Siteman Cancer Care
The Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital is an international leader in cancer treatment, research, prevention, education and community outreach. It is the only cancer center within a 240-mile radius of St. Louis to hold the prestigious Comprehensive Cancer Center designation from the National Cancer Institute and membership in the National Comprehensive Cancer Network.
Siteman offers the expertise of more than 350 Washington University researchers and physicians, who provide care for more than 7,000 newly diagnosed cancer patients each year. A full range of advanced diagnostic and treatment services are available for patients with all types of cancer, from common diseases to rare bone, soft-tissue and adrenal gland cancers.
The Alvin J. Siteman Cancer Center brings together more than 260 scientists who move new cancer therapies from bench to bedside. This process is enhanced by patient access to more than 350 clinical studies, including collaborations with other leading cancer centers. Scientists and physicians affiliated with Siteman hold $130 million in cancer research and related training grants. Their work spans the full spectrum from basic science to translational and clinical investigation, to oncologic imaging, to prevention and control. Research is organized into eight programs, described below:
- Cancer and developmental biology (CDB)
- Cancer genetics
- Cellular proliferation
- Hematopoietic development and malignancy (HDM)
- Oncologic imaging
- Prevention and control
- Translational and clinical research
- Tumor immunology
- Phase I Developmental Therapeutics Unit
Please visit siteman.wustl.edu for more information.
Washington University and Industry Partnerships
As one of the leading medical research institutions in the U.S., Washington University is positioned to collaborate effectively with industry partners in clinical research. The goal for partnerships with industry is the translation of basic research discoveries into products and services for the improvement of human health and well-being.
Washington University takes pride in having formed major corporate collaborations that respect the needs of companies and maintain the principles and autonomy of the academic process and culture. The university's faculty is knowledgeable and responsive to the needs of our corporate partners and understands and meets the expectations of contractual agreements. Together, the university and its partners accomplish what neither is capable of alone.
The university strives to structure agreements that protect the integrity of both the corporation and the university, allowing each to pursue its strengths with assistance from the other. Each agreement is negotiated on a case-by-case basis to take into account the diversity of our constituencies.
Corporate sponsorship of Washington University research puts industry on the front line for early identification of product development opportunities. Timely access to diversified, high-quality biotechnology discoveries gives industry a competitive edge in bringing promising products to market, extending the reach of your in-house R&D and allowing your company to move swiftly into and out of new areas of inquiry.
The university's primary goal in all contract negotiations is to build lasting relationships with corporate sponsors. The university proactively licenses faculty inventions to companies, seeking win-win partnerships that allow the commercial potential of these inventions to be realized.
Faculty often participate in the further development of licensed technology through a sponsored research agreement. These agreements often involve sharing of materials and facilities, moving the invention quickly toward practical applications. Through strategic licensing of uiversity technology, corporate sponsors can obtain the use of new materials to develop products in a timely manner.
Products now on the market based on Washington University technology include a leading diagnostic test for myocardial infarction based on a monoclonal antibody to creatine kinase MB, an improved diagnostic test for herpes simplex virus, a molecular genetic system to study programmed cell death in cancer, a safer type of breast implant, a revolutionary method for treating diabetes based on transplantation of pancreatic islet cells and a breast cancer antigen for immunotherapy of adenocarcinoma.